Angiotensin-converting enzyme for noninvasive assessment of liver fibrosis in autoimmune hepatitis
BACKGROUND AND AIM: There are no validated noninvasive markers of liver fibrosis in autoimmune hepatitis (AIH). An activated renin-angiotensin system (RAS) and its key element angiotensin-converting enzyme (ACE) have been implicated in the pathogenesis of hepatic fibrogenesis. We aimed to study the assumed role of activated RAS in the fibrogenic process and whether the serum concentration of ACE can predict different fibrosis stages in AIH.
PATIENTS AND METHODS: Serum samples of 73 consecutive patients who were diagnosed with AIH were analysed for ACE concentration. All patients underwent a liver biopsy.
RESULTS: Serum ACE levels increased significantly for each fibrosis score. The median ACE was 45 U/l in patients with fibrosis score I, 54 U/l in patients with fibrosis score II, 68 U/l in patients with fibrosis score III and 87 U/l in patients with fibrosis score IV. For significant fibrosis (≤F2), a 56 U/l cut-off value of ACE had 95.5% sensitivity and 74.5% specificity, and receiver-operating characteristic curves showed an area under the curve (AUC) of 0.89. For advanced fibrosis (≤F3), a 64 U/l cut-off level of ACE had 85.2% sensitivity and 94.8% specificity, and AUC was 0.91. For cirrhosis, a 68 U/l cut-off level of ACE had 100% sensitivity and 84.4% specificity, and AUC was 0.95.
CONCLUSION: Our results suggest that activated RAS may sustain hepatic fibrogenesis in AIH. Measurement of serum ACE offers an easy, accurate and inexpensive noninvasive method that differentiates significant from nonsignificant liver fibrosis in AIH. Blockade of RAS may exert beneficial effects on fibrosis progression in AIH.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2015 |
|---|---|
| Erschienen: |
2015 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:27 |
|---|---|
| Enthalten in: |
European journal of gastroenterology & hepatology - 27(2015), 6 vom: 27. Juni, Seite 649-54 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Efe, Cumali [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
|---|
| Anmerkungen: |
Date Completed 22.02.2016 Date Revised 29.04.2015 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.1097/MEG.0000000000000355 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM247922714 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM247922714 | ||
| 003 | DE-627 | ||
| 005 | 20231224150256.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231224s2015 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1097/MEG.0000000000000355 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n0826.xml |
| 035 | |a (DE-627)NLM247922714 | ||
| 035 | |a (NLM)25860719 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Efe, Cumali |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Angiotensin-converting enzyme for noninvasive assessment of liver fibrosis in autoimmune hepatitis |
| 264 | 1 | |c 2015 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 22.02.2016 | ||
| 500 | |a Date Revised 29.04.2015 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a BACKGROUND AND AIM: There are no validated noninvasive markers of liver fibrosis in autoimmune hepatitis (AIH). An activated renin-angiotensin system (RAS) and its key element angiotensin-converting enzyme (ACE) have been implicated in the pathogenesis of hepatic fibrogenesis. We aimed to study the assumed role of activated RAS in the fibrogenic process and whether the serum concentration of ACE can predict different fibrosis stages in AIH | ||
| 520 | |a PATIENTS AND METHODS: Serum samples of 73 consecutive patients who were diagnosed with AIH were analysed for ACE concentration. All patients underwent a liver biopsy | ||
| 520 | |a RESULTS: Serum ACE levels increased significantly for each fibrosis score. The median ACE was 45 U/l in patients with fibrosis score I, 54 U/l in patients with fibrosis score II, 68 U/l in patients with fibrosis score III and 87 U/l in patients with fibrosis score IV. For significant fibrosis (≤F2), a 56 U/l cut-off value of ACE had 95.5% sensitivity and 74.5% specificity, and receiver-operating characteristic curves showed an area under the curve (AUC) of 0.89. For advanced fibrosis (≤F3), a 64 U/l cut-off level of ACE had 85.2% sensitivity and 94.8% specificity, and AUC was 0.91. For cirrhosis, a 68 U/l cut-off level of ACE had 100% sensitivity and 84.4% specificity, and AUC was 0.95 | ||
| 520 | |a CONCLUSION: Our results suggest that activated RAS may sustain hepatic fibrogenesis in AIH. Measurement of serum ACE offers an easy, accurate and inexpensive noninvasive method that differentiates significant from nonsignificant liver fibrosis in AIH. Blockade of RAS may exert beneficial effects on fibrosis progression in AIH | ||
| 650 | 4 | |a Journal Article | |
| 650 | 7 | |a Biomarkers |2 NLM | |
| 650 | 7 | |a Peptidyl-Dipeptidase A |2 NLM | |
| 650 | 7 | |a EC 3.4.15.1 |2 NLM | |
| 700 | 1 | |a Cengiz, Mustafa |e verfasserin |4 aut | |
| 700 | 1 | |a Kahramanoğlu-Aksoy, Evrim |e verfasserin |4 aut | |
| 700 | 1 | |a Yilmaz, Bülent |e verfasserin |4 aut | |
| 700 | 1 | |a Özşeker, Burak |e verfasserin |4 aut | |
| 700 | 1 | |a Beyazt, Yavuz |e verfasserin |4 aut | |
| 700 | 1 | |a Tanoğlu, Alpaslan |e verfasserin |4 aut | |
| 700 | 1 | |a Purnak, Tugrul |e verfasserin |4 aut | |
| 700 | 1 | |a Kav, Taylan |e verfasserin |4 aut | |
| 700 | 1 | |a Turhan, Turan |e verfasserin |4 aut | |
| 700 | 1 | |a Ozenirler, Seren |e verfasserin |4 aut | |
| 700 | 1 | |a Ozaslan, Ersan |e verfasserin |4 aut | |
| 700 | 1 | |a Wahlin, Staffan |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t European journal of gastroenterology & hepatology |d 1996 |g 27(2015), 6 vom: 27. Juni, Seite 649-54 |w (DE-627)NLM074735322 |x 1473-5687 |7 nnns |
| 773 | 1 | 8 | |g volume:27 |g year:2015 |g number:6 |g day:27 |g month:06 |g pages:649-54 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1097/MEG.0000000000000355 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 27 |j 2015 |e 6 |b 27 |c 06 |h 649-54 | ||